Non-formulary methylphenidate (QuilliChew ER™) will be covered on the prescription drug benefit when the following criteria are met:

- Diagnosis of ADHD or ADD
- AND-

1) For patients under age 21:
   - Patient has documented intolerance or contraindication to sprinkle formulations and is unable to swallow whole tablets
   - OR-
   - Patient is already stable on the drug

2) For patients 21 years of age or older NOT currently taking QuilliChew ER™:
   - Adequate trial** (7 days) of methylphenidate ER (Metadate CD or Ritalin LA), unless allergy to an inactive ingredient
   - AND-
   - Adequate trial** (7 days) of methylphenidate ER (Concerta) (must have at least partial response), unless allergy to an inactive ingredient

3) For patients 21 years of age or older currently taking QuilliChew ER™:
   - Adequate trial** (7 days) of methylphenidate ER (Metadate CD or Ritalin LA) (must have at least partial response), unless history of substance abuse or allergy to an inactive ingredient, or currently taking methylphenidate ER (QuilliChew ER) with an antipsychotic or mood stabilizer (lithium or an antiepileptic drug used for mood stabilization)
   - AND-
   - Adequate trial** (7 days) of methylphenidate ER (Concerta) (must have at least partial response), unless allergy to an inactive ingredient, or currently taking methylphenidate ER (QuilliChew ER) with an antipsychotic or mood stabilizer (lithium or an antiepileptic drug used for mood stabilization)
   - OR-
   - Dose change only: patient meets current criteria and is already taking the drug

** Adequate trial of a long acting agent is further defined as wearing off that is not resolved by increasing the dose, AND adding a short-acting agent OR increasing frequency to twice daily OR clinically significant side effects related to the dosage form that cannot be resolved by adjusting the dose or timing.